Grifols, S.A. is set to announce its latest quarterly earnings on Wednesday, April 29th, with a consensus EPS estimate of 0.1613.
Grifols, S.A.'s current price stands at $8.14, showing a slight increase of 1 cent from the previous close. The trading volume is at $232,755, representing a 31.83% rise compared to the average.
The company's latest quarterly earnings were reported on Tuesday, February 24th, with a consensus EPS estimate of 0.29. Stay tuned for the upcoming earnings announcement for potential insights.
Grifols, S.A. offers an attractive forward dividend yield of 8.64% and pays out 17.579 cents per share in dividends both quarterly and trailing twelve months (TTM).
Key financial ratios for Grifols, S.A. include a gross profit margin of 34.68%, operating profit margin of 13.89%, return on equity of 1.86%, and a price-to-earnings ratio of 18.75. Notably, the company maintains a healthy cash position with $1.2 cash per share.
This real-time financial report provides a snapshot of Grifols, S.A.'s current financial standing, upcoming earnings, dividend distributions, and essential financial ratios. Investors should monitor these metrics closely for a comprehensive understanding of the company's performance and outlook.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.